Array Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017

BOULDER, Colo., May 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the third quarter of fiscal 2017 and hold a conference call to discuss those results on Wednesday, May 10, 2017.  Ron Squarer, Chief Executive Officer, will lead the call.

Webcast, including Replay and Conference Call Slides: http://edge.media-server.com/m/p/hgm92o9w

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven registration studies are currently advancing related to seven drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), larotrectinib (partnered with Loxo Oncology), tucatinib (partnered with Cascadian Therapeutics) and ipatasertib (partnered with Roche).

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2017-on-may-10-2017-300450284.html

SOURCE Array BioPharma